Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences unrecognized tax benefits (UTB) — Ending gross balance ($M) ($M)
Form 10-K Note 15 Income Taxes
Latest, FY2025
2,076
Period ended Dec 31, 2025
Change on a year earlier
-10.7%
2,325 in FY2024
History
12 years
Since FY2014
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unrecognized tax benefits (UTB) — Ending gross balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,076 | -10.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 2,325 | +18.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 1,962 | +0.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 1,959 | +14.4% | Form 10-K (filed 2026-02-24) ↗ |
| FY2021 | Dec 31, 2021 | 1,713 | +6.1% | Form 10-K (filed 2025-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 1,614 | -20.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 2,031 | +27.3% | Form 10-K (filed 2023-02-22) ↗ |
| FY2018 | Dec 31, 2018 | 1,595 | -26.9% | Form 10-K (filed 2022-02-23) ↗ |
| FY2017 | Dec 31, 2017 | 2,181 | +17.8% | Form 10-K (filed 2021-02-25) ↗ |
| FY2016 | Dec 31, 2016 | 1,852 | +37.2% | Form 10-K (filed 2019-02-26) ↗ |
| FY2015 | Dec 31, 2015 | 1,350 | +104.2% | Form 10-K (filed 2019-02-26) ↗ |
| FY2014 | Dec 31, 2014 | 661 | – | Form 10-K (filed 2018-02-27) ↗ |
Breakdown
What makes up unrecognized tax benefits (utb) — ending gross balance ($m)
- UTB rollforward — Increases related to current year tax positions ($M)180 · FY2025
- UTB rollforward — Increases related to prior year tax positions ($M)243 · FY2025
- UTB rollforward — Decreases related to prior year tax positions ($M)669 · FY2025
- UTB rollforward — Decreases related to settlements with tax authorities ($M)0 · FY2025
- UTB rollforward — Decreases from lapse of statute of limitations ($M)3 · FY2025
- Unrecognized tax benefits that, if recognized, would affect the effective tax rate ($M)900 · FY2025
- Accrued interest and penalties related to unrecognized tax benefits ($M)176 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Unrecognized tax benefits (UTB) — Ending gross balance ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/utb_tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.